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Cyclic changes in behaviour and mood which do not meet the criteria for bipolar affective
disorder have been reported in people with intellectual disability (ID) since the beginning of the
twentieth century. The present study postulates a functional disturbance of unstable mood
disorder in such cases of an episodic pattern of disturbed behaviour, mood and anxiety. Since
symptoms of hypomania or major depression are not observed in these individuals, the unstable
mood disorder cannot be regarded as being part of the bipolar spectrum, although it resembles
cyclothymia in some aspects. In this pilot study, 28 subjects with ID were treated with valproic
acid in dosages leading to a mean plasma concentration of 63 mg L1. A marked and sustained
improvement was achieved in 68% of subjects in terms of both behaviour stability, and a
reduction of symptoms in the mood, anxiety and motor domains.
Introduction
Ever since the involvement of psychiatry in the care of people with intellectual disability
(ID), descriptions of episodic mood changes which do not meet the criteria for a major
affective disorder have been published. At the beginning of the twentieth century, the
French psychiatrist Sollier (1901) described sudden mood swings associated with
anxiety, changes in motor activity and challenging behaviours which could be distin-
guished from manic episodes. Similar observations have been made in the German
literature. For example, Bumke (1929) reported rapid changes in affect and behaviour
which were considered to be a specific psychopathological entity. Emotional instability
characterized by rapid mood changes, irritability and dysphoria has also clearly been
delineated form manic depressive illness in British studies (Duncan 1936). In the more
recent literature, Gualtieri (1991) also emphasized the resemblance to affective disorders
in organic brain syndromes which do not easily meet the criteria for DSM-IV classifica-
tion. Such conditions have been described under several headings, such as atypical
bipolar syndromes, mixed states with features of depression and mania, unipolar mania,
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cyclothymia, dysthymia, and rapid cycling bipolar disorders (Ruedrich 1993; Akiskal
1994, 1996; Vanstraelen & Tyrer 1999).
In line with the original descriptions from the western European tradition, Meins
(1994) concluded from factor analytic studies that a symptom cluster characterized by
mood swings, irritability, impulsivity, aggression and self-injury can be identified in
subjects with ID. Matson et al. (1991) made comparable observations in a study involving
506 people with ID: a factor emerged including rapid mood changes, crying, periods
of sudden motor or vocal activities, and episodic aggression dysregulation. Finally,
in a review by Einfeld & Aman (1995), it was noted that emotional lability as a factor is
either accompanied by aggressive and impulsive behaviour, or by anxious symptoms
and self-injury.
Therefore, on the basis of these considerations, the present authors recently postulated
the concept of unstable mood disorder in cases characterized by a cyclic alteration of
behaviour associated with an episodic pattern of disturbed mood and/or anxiety
(Verhoeven & Tuinier 1999, 2000).
The present pilot study describes the effects of valproic acid treatment on individuals
with ID suffering from unstable mood disorder.
Subjects and methods
Subjects were recruited from a sample of 248 individuals, living in more than 20 different
residential settings, who were referred for neuropsychiatric evaluation to one of the
present authors (W.M.A.V.) over a period of 3 years. The functional disturbance of
unstable mood disorder was ascertained primarily on the basis of rapid or episodic
fluctuations in behaviour in general, and secondarily, on the presence of prominent
mood deviations eventually accompanied by dysphoria, irritability, anxieties and/or
motor signs such as hyperactivity, stereotypies, self-injuries and aggression. Subjects
with a clear neuropsychiatric diagnosis such as uni- or bipolar major affective disorder,
psychotic disorder, obsessive compulsive disorder, epilepsy-related behaviour dyscon-
trol or challenging behaviours within the context of an established psychiatric aetiology
were excluded. In no case was any manifestation of hypomania or major depression
noticed.
This selection procedure resulted in a sample group of 28 subjects with ID in the mild
to severe range. All individuals in the group had a long history of episodic changes in
behaviour and affect. Treatment with various psychotropic drugs, such as antipsycho-
tics, antidepressants and anxiolytics, as well as numerous behavioural interventions, had
not resulted in a sustained reduction or prevention of their challenging behaviours,
which comprised aggression, self-injury, irritability and agitation. The main character-
istics of the subjects are presented in Table 1. The specific aetiologies included trisomy 21
(n¼ 2), incomplete trisomy 15 (n¼ 1), congenital hypothyroidism (n¼ 1) and micro-
cephaly (n¼ 1). Neurological or somatic comorbidity was present in 11 subjects, while
a psychiatric diagnosis had been previously established according to the medical record
in 20 participants.
All subjects were examined in their residential settings and examples of behavioural
abnormalities were videotaped in all cases. A history was obtained from the subjects’
interdisciplinary team members as well as from the medical records, including labora-
tory test results, psychological assessments and behavioural data. There was a recent
clinical genetics work-up for all subjects.
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Standard clinical interviews could not be used since most of the subjects were not
sufficiently verbally competent. Diagnostic assessments relied heavily on the beha-
vioural components of psychiatric disorders. Diagnoses of a probabilistic nature were
established during multidisciplinary consensus meetings and were based on the ICD-10
clinical descriptions and diagnostic guidelines (WHO 1992). After having defined the
specific components of each subject’s functional disturbance, the frequency and intensity
of target symptoms from the mood, anxiety and motor domains were monitored at
biweekly intervals by staff members applying visual analogue scales. Based on these
data, a baseline-controlled design was followed and the general treatment effect was
assessed during multidisciplinary meetings at 3-month intervals by using the Clinical
Global Improvement Scale (CGIS; Guy 1976). The CGIS comprises a clinician rating
of the individual treatment effect and its items are scaled from (1) ‘very much improved’
to (7) ‘very much worse’. A final evaluation was made after 6 months (n¼ 7) or one
year.
Concomitant medication was stable for at least 3 months prior to the beginning of the
experiment and was kept unchanged over the first 12 weeks of treatment. Co-medication
(except for anticonvulsants in the three subjects with epilepsy) was tapered off in case
Table 1 Characteristics of the subjects (n¼ 28)
Characteristic Number
Age and sex
Sex:
male 18
female 10
Age (years):
mean 37.3
range 18–66
Aetiology
Unknown 16
Perinatal complications 6
Encephalitis postvaccinalis 1
Specific syndromes 5
Neurological or somatic comorbidity
Epilepsy 3
History of epilepsy 5
Tardive dyskinesia 1
Renal transplantation 1
Traumatic cataract 1
Previous psychiatric diagnoses
Mood disorder 12
(Atypical) autism 4
Psychotic disorder 3
Panic disorder 1
Current medication
Anticonvulsants for epilepsy 3
Anticonvulsants for behavioural control 2
Antipsychotics 20
Antidepressants 6
Anxiolytics 8
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of a positive therapeutic response. The tapering-off period was between 6 weeks and
3 months depending on dosage and duration of pharmacological treatment.
In all subjects, treatment with valproic acid started at a daily dosage of 300 mg and this
was subsequently increased over a period of 6 weeks. Dosage adjustments were made to
obtain a plasma concentration of at least 60 mg L1 unless a response was clearly
achieved at a lower level. The guidelines of the Dutch Association of Psychiatry
recommend a plasma concentration of valproic acid of 60–80 mg L1 for maintenance
therapy for bipolar affective disorder.
Results
Valproic acid was prescribed in 28 subjects within a dose range of 300–3000 mg day1
(mean SD¼ 1345 619 mg day1), leading to a mean plasma concentration of
63 mg L1 (SD¼ 17 mg L1; range¼ 20–96 mg L1). No major side-effects were observed.
Premature discontinuation of treatment did not have to be considered in any of the
subjects because of behavioural deterioration, intercurrent illnesses or pharmacokinetic
interactions. A follow-up period of at least one year was achieved in 21 subjects. In the
other seven subjects, this period comprised 6 months only. The dosage of valproic acid
was kept unchanged over the total follow-up period in all the subjects.
As assessed with the CGIS, a moderate to marked improvement (much and very
much) was observed in 19 participants. As a rule, the improvement was comprised of a
stabilization of behaviour and mood, as well as a reduction of symptoms belonging to the
mood, anxiety and motor domains (Table 2). Minimal changes or no improvement
at all were noted in nine subjects (Table 3).
In three subjects using carbamazepine, the addition of valproic acid resulted in a
marked improvement without changes in plasma concentrations of carbamazepine. One
subject was already being treated for epilepsy with valproic acid at a dosage of
900 92 mg day1 (92 mg L1). A dose reduction to 600 mg day1 (45 mg L1) unexpect-
edly resulted in a moderate stabilization of mood and behaviour.
Table 2 Functional domains of unstable mood disorder (n¼ 28)
Domain Number Percentage
Mood
Rapid mood swings 6 21
Mood swings 16 57
Episodic dysphoria 16 57
Anxiety
Anxieties 7 25
Irritability 13 46
Motor
Disorganized behaviour 6 21
Hyperactivity 13 46
Stereotypies 10 36
Self-injuries 7 25
Impulsivity 7 25
Aggression 15 54
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At the baseline, responders (n¼ 19) and non-responders (n¼ 9) did not differ with
respect to age and the types of symptoms belonging to the three domains. At the
endpoint, no differences could be demonstrated between both response groups with
regard to either the dosage or plasma concentration of valproic acid. The tapering
off of co-medication after having achieved moderate to marked improvement did not
influence the clinical response nor the stability of behaviour. Psychotropic co-medication
was not related to the degree or nature of the clinical response.
Discussion
In the present exploratory pilot study, the effect of valproic acid was investigated in 28
subjects with ID who were assumed to suffer from unstable mood disorder characterized
by long-lasting episodic disturbances in the mood, anxiety and motor domains. Ideally, a
time-series analysis is appropriate to assess treatment effects in subjects with fluctuating
symptomatology. However, the CGIS has a widespread application in psychiatry and its
validity has been established in affective disorders (Leon et al. 1993). A clinically relevant
and sustained improvement in terms of both behaviour stability and symptom reduction
was observed in 68% of the subjects. The treatment effects of valproic acid were noticed
at a mean daily dose level and mean plasma concentration of 1343 mg day1 and
63 mg L1, respectively.
Because no signs of hypomania or major depression were observed, the disorder in
these subjects cannot be regarded as belonging to the bipolar spectrum with or without
Table 3 Global improvement versus current illness state at endpoint in subjects treated with
valproic acid (n¼ 28)
Global improvement
Severity of
illness state
Very much
improved
Much
improved
Minimal
improvement
No
improvement
Total
Normal:
number 1 1
percentage 3.6 3.6
Marginal:
number 8 1 9
percentage 28.6 3.6 32.1
Mild:
number 7 7
percentage 25.0 25.0
Moderate:
number 2 2 4
percentage 7.1 7.1 14.3
Severe:
number 4 4
percentage 14.3 14.3
Very severe:
number 3 3
percentage 10.7 10.7
Total:
number 9 10 2 7 28
percentage 32.1 35.7 7.1 25.0 100
Journal of Applied Research in Intellectual Disabilities 151
# 2001 BILD Publications, Journal of Applied Research in Intellectual Disabilities, 14, 147–154
a rapid cycling course. The mere finding that valproic acid is effective in the majority of
the subjects included in the present controlled treatment study does not automatically
imply that the unstable mood disorder belongs to the bipolar affective disorders. Thus,
the results cannot easily be compared with those obtained by others investigating
subjects with ID and bipolar affective disorders (Sovner 1989; Kastner et al. 1993;
Ruedrich et al. 1999). The diagnostic category of atypical or unspecified bipolar disorder
is most probably given in many cases (Deltito 1993; Jacobsen 1993; Gross & Huber 1996).
The present authors have previously reported an ICD-10 diagnosis of unspecified
bipolar affective disorder in 14 subjects described in a study of neuropsychiatric
consultations in 70 institutionalized subjects with ID, (Verhoeven & Tuinier 1997).
The unstable mood disorder proposed in the present paper resembles the description
of the ICD-10 diagnosis of cyclothymia (F34.0), in which cyclic changes in behaviour and
sociability may dominate (WHO 1992), but lacks periods of elation. As elegantly
observed by Gualtieri (1991), subjects with developmental disorders frequently show
affective symptoms which may be extremely debilitating and may require intensive
pharmacological treatment, but which only occasionally meet the diagnostic criteria for a
discrete major affective episode. The problematic nosological status of sub-affective
syndromes, such as cyclothymia, has been debated in the psychiatric literature for more
than a century (Brieger & Marneros 1997).
The relatively low prevalence of subjects with epilepsy in the present study may be
related to either a stabilizing effect of anticonvulsants in general or an interference of
these compounds with neurobiological stress-regulating mechanisms (Verhoeven et al.
1999). The latter holds particularly for valproic acid since this anticonvulsant acts
on the hippocampal serotonin 1a receptor that is involved in stress reactivity (Shiah
et al. 1977).
As reviewed by Guay (1995) and Davis et al. (2000), disorders which respond in general
to valproic acid share elements of psychopathology such as mood instability, beha-
vioural dyscontrol, anxiety, impulsivity, agitation and hyperarousal. This advocates a
dimensional approach with behavioural elements and symptoms which cut across
psychiatric diagnoses. Such a perspective is in agreement with the functional psycho-
pathological paradigm advocated for many years by H. M. Van Praag (Van Praag &
Leijnse 1965; Van Praag et al. 1990). In cases of so-called unstable mood disorder,
the relevant functional disturbance is instability, which entails episodic changes in
behaviour, mood and anxiety (Verhoeven & Tuinier 2000).
Although it can be argued that the present study has methodological shortcomings, a
clear symptom profile, albeit an inter-individually different one, of unstable mood
disorder in people with ID could be identified that appears to be responsive to treatment
with valproic acid. Given this profile, future studies should include the Aberrant
Behavior Checklist (Aman 1985) since its items cover the anxiety and motor domains.
However, heterogeneity in genetic aetiology and level of ID, as well as somatic and
neurological comorbidity, still warrants a multiple n¼ 1 design.
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